BERKELEY, CA (UroToday.com) - Presented by James L. Gulley, MD, PhD, FACP
BERKELEY, CA USA (UroToday.com) - Presented by Leonard Gomella, MD, Clinical Director Jefferson Kimmel Cancer Center Network, Philadelphia, PA USA
Six different treatments have demonstrated improved survival in phase III trials targeted to patients with metastatic castration-resistant prostate cancer (mCRPC).
ORLANDO, FL, USA (UroToday.com) - Presented by Charles G. Drake, MD, PhD, Associate Professor; Medical Oncology, Immunology, and Urology; Co-director Multi-disciplinary Prostate Cancer Clinic; Johns Hopkins Kimmel Cancer Center; Baltimore, MD USA
Prostate cancer is the most common cancer in men and the second most deadly. About one-third of patients with prostate cancer will develop metastatic disease. We discuss the six United States Food and Drug Administration (FDA) approved treatments for metastatic castrate-resistant prostate cancer (mCRPC) with a strong focus on sipuleucel-T.
Page 2 of 2
Login to update email address, newsletter preferences and use bookmarks.
Email
Password